HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.

International Conference on Medicinal Chemistry, Computer Aided Drug Design and Delivery

September 14-16, 2023

September 14 -16, 2023 | Valencia, Spain
MCADD 2023

Philip M Hemken

Speaker at Medicinal Chemistry, Computer Aided Drug Design and Delivery 2023 - Philip M Hemken
Abbott Laboratories, United States
Title : Abbott diagnostics: COVID-19 inactivation, nucleocapsid antigen automated immunoassay development, and variant testing for automated and lateral flow assays binaxnow™ and panbio™

Abstract:

Dr. Hemken will describe the viral inactivation of SARS?CoV?2 with the detergent Tergitol 15?S?9. In the process of
developing a prototype immunoassay on the ARCHITECT automated analyzer for detecting the SARS?CoV?2 antigen, we discovered heat inactivation reduced the detection of recombinant full?length SARS?CoV?2 nucleocapsid protein and virus lysate by 66% and 31%, respectively. We examined several non?ionic detergents as inactivation alternatives in the cell culture model and ARCHITECT. Tergitol 15?S?9 can inactivate SARS?CoV?2 in as little as 10 minutes while preserving epitopes on the nucleocapsid protein and boosting the immunoassay signal. Mutations in the nucleocapsid of SARS?CoV?2 may interfere with antigen detection by diagnostic tests. We used several methods to evaluate the effect of various SARS?CoV?2 nucleocapsid mutations on the performance of the Panbio™ and BinaxNOW™ lateral flow rapid antigen tests and a prototype high?throughput immunoassay. Variant detection was also evaluated by immunoblot and BIAcore™ assay. A panel of 23 recombinant nucleocapsid antigens (rAg) was produced that included mutations found in circulating SARS?CoV?2 variants, including variants of concern. All mutant rAg were detected by all assays, at a sensitivity equivalent to the wild-type control (Wuhan strain). Thus, using a rAg approach, we found that the SARS?CoV? 2 nucleocapsid mutations examined do not directly impact antigen detection or antigen assay performance.

Biography:

Dr. Philip Hemken, Ph.D., is a Principal Research Scientist in the Diagnostics Division of Abbott Laboratories. He manages the Protein Engineering team within Global Biologics Discovery. He got his BSc in Microbiology (Chemistry Minor) from Iowa State University of Science and Technology in 1986, MA in Biotechnology from Washington University in St. Louis in 1991, and Ph.D. in Molecular, Cellular, and Developmental Biology from Iowa State University of Science and Technology in 1996 followed by a Postdoc in the Biology Division at Argonne National Laboratories (1996‐1997). Currently, Dr. Hemken manages the Protein Engineering team in the Global Biologics Discovery organization at Abbott Laboratories (2016‐present). Dr. Hemken started in the Abbott Diagnostics Division at Abbott in 1997 working in product support (1997‐1998), followed by Molecular Diagnostics (1998‐2004), and Automated Immunoassay Development (2005‐2016). He has completed 14 immunoassay prototyping projects and managed the production of recombinant biologics for 27 immunoassay development projects. Dr. Hemken has 28 publications, 38 patent applications with 13 issued patents. Dr. Hemken resides in Pleasant Prairie, WI, and enjoys spending year‐round time with his wife Ann at their lake home in Northern Wisconsin hiking, biking, swimming, and skiing. He also enjoys woodworking and antique cars.

Watsapp